PCSK9 inhibitor
Pronunciation: P-C-S-K-nine in-HIB-it-or
Also written as: PCSK9i — proprotein convertase subtilisin/kexin type 9 inhibitor
A class of injectable medications that dramatically lower LDL cholesterol levels.
Full Definition
PCSK9 inhibitors are monoclonal antibodies that block the proprotein convertase subtilisin/kexin type 9 enzyme, which normally degrades LDL receptors in hepatocytes. By inhibiting PCSK9, these medications increase LDL receptor availability, dramatically enhancing cholesterol uptake by the liver and reducing circulating LDL cholesterol by 50-70%. Currently available agents include evolocumab and alirocumab, which are administered as subcutaneous injections every two weeks or monthly.
Usage
Usage note: Spell out 'PCSK9' rather than using numerals. Hyphenate when used as compound modifier.
In Context
- "The addition of a PCSK9 inhibitor reduced the patient's LDL cholesterol from 180 to 65 mg/dL." — Treatment response note
- "PCSK9 inhibitor therapy is indicated for patients with familial hypercholesterolemia or statin intolerance." — Prescription rationale